Maxim Group Begins Coverage on Kintara Therapeutics (NASDAQ:KTRA)

Maxim Group began coverage on shares of Kintara Therapeutics (NASDAQ:KTRA) in a research note issued to investors on Friday, TipRanks reports. The firm issued a buy rating and a $3.00 price target on the stock.

Separately, Aegis reiterated a buy rating and issued a $6.00 price objective on shares of Kintara Therapeutics in a research report on Thursday, October 1st.

NASDAQ KTRA opened at $1.45 on Friday. The business’s fifty day moving average is $1.48. The stock has a market cap of $35.76 million, a price-to-earnings ratio of -1.65 and a beta of 1.82. Kintara Therapeutics has a 52 week low of $0.38 and a 52 week high of $1.95.

Kintara Therapeutics (NASDAQ:KTRA) last released its quarterly earnings data on Monday, September 21st. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.16). As a group, equities analysts predict that Kintara Therapeutics will post -0.34 earnings per share for the current year.

An institutional investor recently bought a new position in Kintara Therapeutics stock. IPG Investment Advisors LLC purchased a new stake in Kintara Therapeutics, Inc. (NASDAQ:KTRA) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 26,000 shares of the company’s stock, valued at approximately $36,000. IPG Investment Advisors LLC owned 0.11% of Kintara Therapeutics as of its most recent filing with the SEC. 2.14% of the stock is currently owned by institutional investors.

About Kintara Therapeutics

Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.

Featured Story: Should I follow buy, hold and sell recommendations?

Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with's FREE daily email newsletter.